R&D Network: Cancer biomarkers and targeted therapy

Thursday October 15th, at 13:00-18:00 in Bergen

CCBIO microscope image

Foto/ill.:

CCBIO

Hovedinnhold

Moderator of the day: Professor Bjørn Tore Gjertsen, Centre for Cancer Biomarkers, University of Bergen/Clinical Trial Unit, Haukeland University Hospital.

Preliminary program:

13:00–13:30	Registration, light refreshments and rigging posters
13:30–13:45	Welcome and update on Oslo Cancer Cluster Incubator - Ketil Widerberg, general manager Oslo Cancer Cluster and Bjørn Klem OCC Incubator
13:45–14:05	“Signalling-targeted therapy” - Prof. Bjørn Tore Gjertsen
14:05–14:25	“Current concepts and challenges in cancer research” - Prof. Lars A. Akslen, Director,Centre for Cancer Biomarkers, University of Bergen
14:25-14.30	10 min break
14:30–15:20	International key note: “Targeted therapies in lung cancer” - Dr Matthew Krebs, Institute of Cancer Sciences, University of Manchester Q&A
15:20–15:30	10 min coffee break
15:30–15:45	Company updates: BergenBio - Richard Godfrey, CEO
15:45–16:00	Alden Cancer Therapy - Bjørn Tore Gjertsen, Board Member
16:00–16.15	Oncology projects – BTO update - Anders Haugland, managing director
16:15–16.25	Concluding remarks from moderator - Bjørn Tore Gjertsen
16:25–18.00	Young researchers poster session Networking session/standing dinner with tapas

Welcome to all!

Please find printer friendly program here.

Seminar

15.10.2015 - 13.00–18.00

Auditorium 4, BB-Building, Jonas Lies vei 91, Bergen

Påmeldingsfrist

08.10.2015 - 12.00

Legg til i din egen kalender

R&D Network Meetings

The R&D Network Meetings are Oslo Cancer Cluster´s signature events for members and associated partners, and are arranged four to five times annualy.

The purpose with these meetings is to gather people from every member segment, representating the whole value chain, and encourage information exchange and innovative collaborations across diciplines.

The R&D Network Meetings features relevant oncology topics, for example clinical trials or kidney cancer, and several speakers will then highlight the topic from their point of view representing all member segments from basic research to international pharma. After the presentations everyone is encouraged to further network and discussion.

22.09.2015